Strategies to circumvent SV40 oncoprotein expression in malignant pleural mesotheliomas
Authors:
- David S SchrumpDSDavid S Schrump
- Ishrat WaheedIWIshrat Waheed
- 28 February 2001
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 11 (1) , 73-80
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivoOncogene, 2000
- Simian Virus 40 Large T Antigen Binds a Novel Bcl-2 Homology Domain 3-containing Proapoptosis Protein in the CytoplasmJournal of Biological Chemistry, 2000
- Clinical studies of antisense therapy in cancerFrontiers in Bioscience-Landmark, 2000
- New molecular and epidemiological issues in mesothelioma: Role of SV40Journal of Cellular Physiology, 1999
- The INK4a/ARF tumor suppressor: one gene—two products—two pathwaysTrends in Biochemical Sciences, 1998
- Oncogenes and Tumor-Suppressor Genes in Mesothelioma: A SynopsisEnvironmental Health Perspectives, 1997
- Recent advances on cyclins, CDKs and CDK inhibitorsTrends in Cell Biology, 1997
- Cancer Cell CyclesScience, 1996
- Cyclins and cancer II: Cyclin D and CDK inhibitors come of ageCell, 1994
- The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large TCell, 1990